Novo Cure LTD NVCR
We take great care to ensure that the data presented and summarized in this overview for NovoCure Ltd is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NVCR
View all-
Vanguard Group Inc Valley Forge, PA10MShares$181 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.08MShares$164 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA8.86MShares$160 Million0.03% of portfolio
-
State Street Corp Boston, MA3.36MShares$60.7 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.38MShares$42.9 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA2.31MShares$41.6 Million0.01% of portfolio
-
Baillie Gifford & CO1.99MShares$35.9 Million0.02% of portfolio
-
Morgan Stanley New York, NY1.76MShares$31.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.64MShares$29.6 Million0.0% of portfolio
-
Nordwand Advisors, LLC Radnor, PA1.52MShares$27.3 Million9.2% of portfolio
Latest Institutional Activity in NVCR
Top Purchases
Top Sells
About NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Insider Transactions at NVCR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 05
2024
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
124,373
+50.0%
|
$2,736,206
$22.82 P/Share
|
|
Jun 05
2024
|
Allyson J Ocean |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+50.0%
|
-
|
|
Jun 05
2024
|
Martin J. Madden |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+17.08%
|
-
|
|
Jun 05
2024
|
David Hung |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+23.5%
|
-
|
|
Jun 05
2024
|
Gabriel Leung |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+4.65%
|
-
|
|
Jun 05
2024
|
Timothy J Scannell |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+33.68%
|
-
|
|
Jun 05
2024
|
W Anthony Vernon |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+2.33%
|
-
|
|
Jun 05
2024
|
Kristin Stafford |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+50.0%
|
-
|
|
Jun 05
2024
|
Jeryl L Hilleman |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+38.08%
|
-
|
|
Jun 04
2024
|
Gabriel Leung |
SELL
Open market or private sale
|
Direct |
964
-1.22%
|
$22,172
$23.89 P/Share
|
|
Jun 04
2024
|
Timothy J Scannell |
SELL
Open market or private sale
|
Direct |
964
-24.54%
|
$22,172
$23.89 P/Share
|
|
Jun 04
2024
|
W Anthony Vernon |
SELL
Open market or private sale
|
Direct |
964
-0.58%
|
$22,172
$23.89 P/Share
|
|
Mar 04
2024
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,217
-0.48%
|
$19,472
$16.01 P/Share
|
|
Mar 04
2024
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
840
-0.52%
|
$13,440
$16.01 P/Share
|
|
Mar 01
2024
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,107
-0.83%
|
$33,712
$16.03 P/Share
|
|
Mar 01
2024
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
1,679
-1.03%
|
$26,864
$16.03 P/Share
|
|
Feb 28
2024
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
2,078
-1.26%
|
$33,248
$16.14 P/Share
|
|
Feb 28
2024
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,303
-0.9%
|
$36,848
$16.14 P/Share
|
|
Feb 27
2024
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
102,249
+31.74%
|
$1,635,984
$16.3 P/Share
|
|
Feb 27
2024
|
Nicolas Leupin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
51,124
+50.0%
|
$817,984
$16.3 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 662K shares |
|---|---|
| Exercise of conversion of derivative security | 142K shares |
| Open market or private sale | 16.1K shares |
|---|